2023
Safety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis
Pasta A, Calabrese F, Jaffe A, Labanca S, Marenco S, Pieri G, Torres M, Strazzabosco M, Giannini E. Safety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis. Liver Cancer 2023, 13: 235-245. PMID: 38756146, PMCID: PMC11095597, DOI: 10.1159/000533991.Peer-Reviewed Original ResearchChild-Pugh class B patientsChild-Pugh B patientsClass B patientsObjective response rateProgression-free survivalChild-Pugh AB patientsOverall survivalHepatocellular carcinomaAdverse eventsLiver functionOdds ratioChild-Pugh class A patientsTreatment-related adverse eventsChild-Pugh class AHigher objective response rateShorter progression-free survivalMedian overall survivalAlbumin-bilirubin gradeImpaired liver functionClass A patientsUnresectable hepatocellular carcinomaIndividualization of treatmentChild-PughALBI gradeSystematic review and meta-analysis of safety and efficacy of atezolizumab/ bevacizumab in Child-Pugh class B patients with hepatocellular carcinoma
Pasta A, Calabrese F, Jaffe A, Labanca S, Marenco S, Pieri G, Torres M, Strazzabosco M, Giannini E. Systematic review and meta-analysis of safety and efficacy of atezolizumab/ bevacizumab in Child-Pugh class B patients with hepatocellular carcinoma. Digestive And Liver Disease 2023, 55: s221. DOI: 10.1016/j.dld.2023.08.025.Peer-Reviewed Original ResearchChild-Pugh class B patientsClass B patientsDisease control rateObjective response rateImpaired liver functionB patientsHepatocellular carcinomaLiver functionChild-Pugh B cirrhosisTreatment-related adverse eventsHigher objective response rateAdverse events gradeBest supportive careMedian overall survivalProgression-free survivalIndividualization of treatmentClass AB cirrhosisChild-PughCohort studyFree survivalOverall survivalSupportive careAdverse eventsOncological efficacy
2022
Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook
Jaffe A, Taddei TH, Giannini EG, Ilagan‐Ying Y, Colombo M, Strazzabosco M. Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook. Liver International 2022, 42: 2607-2619. PMID: 36161463, PMCID: PMC10878125, DOI: 10.1111/liv.15432.Peer-Reviewed Original ResearchConceptsLiver diseaseHepatocellular carcinomaLiver functionRisk factorsRelevant prognostic roleChronic hepatitis BResidual liver functionChronic liver diseaseManagement of patientsCare of patientsCommon risk factorsAppropriate surveillance strategiesSuccessful cancer treatmentC infectionCommon complicationHepatitis BMetabolic syndromePrognostic roleSignificant morbidityLongitudinal careCurrent careCancer recurrenceHCC managementLiver cancerHCC treatment
2016
Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study
Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, Martini S, Morelli C, Donato F, Volpes R, Pageaux GP, Coilly A, Fagiuoli S, Amaddeo G, Perricone G, Vinaixa C, Berlakovich G, Facchetti R, Polak W, Muiesan P, Duvoux C, Association E. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. Journal Of Hepatology 2016, 65: 524-531. PMID: 27212241, DOI: 10.1016/j.jhep.2016.05.010.Peer-Reviewed Original ResearchConceptsDirect acting antiviralsOral direct acting antiviralsClinical improvementChild-PughLiver transplantationActing antiviralsAdvanced liver diseaseChronic hepatitis CLiver transplant candidatesLow MELD scoresRemarkable clinical improvementHepatitis C virusDAA therapyDelta MELDDelta-albuminDAA combinationsHepatitis CMELD scoreViral eradicationCumulative incidenceLiver dysfunctionTransplant candidatesAntiviral therapyLiver diseaseLiver function
2012
Polycystic liver diseases
Fabris L, McCrann C, Strazzabosco M. Polycystic liver diseases. 2012, 713-718. DOI: 10.1002/9781118321386.ch96.ChaptersPolycystic liver diseaseLiver diseaseCongenital hepatic fibrosisAutosomal dominant polycystic liver diseaseDifferent clinical entitiesChronic complicationsKidney involvementLiver transplantationPortal hypertensionCaroli's diseaseMedical therapyClinical entityLiver functionMultiple cystsSurgical approachHepatic fibrosisBiliary epitheliumHepatic parenchymaLiver parenchymaProgressive enlargementInterventional radiologyDiseaseGenetic defectsEndoplasmic reticulum-associated proteinParenchyma
1987
Antipyrine Clearance: Evaluation of Simplified Methods in Chronic Liver Diseases
Strazzabosco M, Muraca M, Venuti M, Varotto A, Nassuato G, Iemmolo R, Orlando R, Lirussi F, Manzati C, Crimella T, Iaccheri E, Bernardi R, Okolicsányi L. Antipyrine Clearance: Evaluation of Simplified Methods in Chronic Liver Diseases. 1987, 197-204. DOI: 10.1007/978-3-642-72631-6_26.Peer-Reviewed Original ResearchLiver diseaseAntipyrine clearanceChronic liver diseaseHepatic blood flowHepatic drug metabolismHepatic microsomal enzymesLarge interindividual variationOne-compartment modelSurgical riskLiver functionClinical hepatologyTotal body waterLiver patientsBlood flowDistribution volumeDrug metabolismPrognostic purposesInterindividual variationMicrosomal enzymesBody waterDiseaseClearancePatientsUnique kinetic propertiesHepatology